In the Claims

Please cancel claim 1, without prejudice, and add the following new claims.

1. (Cancelled)

2. (New) A method, comprising:

applying, to a tissue surface internally of a mammal, an initially entirely fluent, pre-polymeric material, the pre-polymeric material comprising at least one therapeutic agent, the pre-polymeric material being activatable to a non-fluent, polymeric condition; and

polymerizing the pre-polymeric material on the tissue surface to form thereon a layer of polymeric, non-fluent material.

3. (New) The method of claim 1, wherein the polymerizing step comprises heating the pre-polymeric material.

4. (New) The method of claim 1, wherein the polymerizing step comprises cooling the pre-polymeric material.

5. (New) The method of claim 1, wherein the polymerizing step comprises mechanically deforming the pre-polymeric material.

6. (New) The method of claim 1, wherein the polymerizing step comprises chemically reacting the pre-polymeric material.

7. (New) The method of claim 1, wherein the polymerizing step comprises cross-linking the pre-polymeric material.

8. (New) The method of claim 1, wherein the polymerizing step comprises applying radiation to the pre-polymeric material.

9. (New) The method of claim 1, wherein the polymeric, non-fluent material is biodegradable.

10. (New) The method of claim 1, wherein the polymeric material comprises at least one of a carboxylic acid, a polyurethane, a polyester, a polyamide, a polyphosphazine, a polylactone, a polyanhydride, polyethylene, polyvinyl chloride, ethylene vinyl acetate, delta-valerolactone, and p-dioxanone.

11. (New) The method of claim 1, wherein the polymeric material comprises polycaprolactone.

12. (New) The method of claim 1, wherein the tissue is cardiac tissue.

13. (New) The method of claim 1, wherein the tissue is muscle tissue.

14. (New) The method of claim 1, wherein the tissue has a hollow geometry.

15. (New) The method of claim 1, wherein the tissue is a blood vessel.

16. (New) The method of claim 1, wherein the therapeutic agent comprises a growth factor.

17. (New) The method of claim 1, wherein the therapeutic agent comprises an anti-thrombotic agent.

18. (New) The method of claim 16, wherein the anti-thrombotic agent comprises prostacyclin.

19. (New) The method of claim 16, wherein the anti-thrombotic agent comprises a salicylate.

20. (New) The method of claim 1, wherein the therapeutic agent comprises a thrombolytic agent.

21. (New) The method of claim 19, wherein the thrombolytic agent comprises streptokinase.

22. (New) The method of claim 19, wherein the thrombolytic agent is urokinase.

23. (New) The method of claim 19, wherein the thrombolytic agent comprises tissue plasminogen activator.

24. (New) The method of claim 19, wherein the thrombolytic agent comprises anisoylated plasminogen-streptokinase activator complex.

25. (New) The method of claim 1, wherein the therapeutic agent comprises a vasodilating agent.

26. (New) The method of claim 24, wherein the vasodilating agent comprises a nitrate.

27. (New) The method of claim 24, wherein the vasodilating agent comprises a calcium channel blocker.

28. (New) The method of claim 1, wherein the therapeutic agent comprises an anti-proliferative agent.

29. (New) The method of claim 27, wherein the anti-proliferative agent comprises colchicine.

30. (New) The method of claim 27, wherein the anti-proliferative agent comprises an alkylating agent.

31. (New) The method of claim 1, wherein the therapeutic agent comprises an intercalating agent.

32. (New) The method of claim 1, wherein the therapeutic agent comprises a growth modulating factor.

33. (New) The method of claim 31, wherein the growth modulating factor comprises an interleukin.

34. (New) The method of claim 31, wherein the growth modulating factor comprises transformation growth factor beta.

35. (New) The method of claim 31, wherein the growth modulating factor comprises a congener of a platelet derived growth factor.

36. (New) The method of claim 1, wherein the therapeutic agent comprises a monoclonal antibody.

37. (New) The method of claim 1, wherein the therapeutic agent comprises an anti-inflammatory agent.

38. (New) The method of claim 36, wherein the anti-inflammatory agent is steroidal.

39. (New) The method of claim 36, wherein the anti-inflammatory agent is non-steroidal.

40. (New) The method of claim 1, wherein the therapeutic agent is able to modulate vessel tone.

41. (New) The method of claim 1, wherein the therapeutic agent is able to modulate arteriosclerosis.

42. (New) The method of claim 1, wherein the therapeutic agent is able to modulate the healing response of the tissue surface.